Your browser doesn't support javascript.
loading
Long-term subjective cognitive functioning following adjuvant systemic treatment: 7-9 years follow-up of a nationwide cohort of women treated for primary breast cancer.
Amidi, A; Christensen, S; Mehlsen, M; Jensen, A B; Pedersen, A D; Zachariae, R.
Afiliación
  • Amidi A; Unit for Psychooncology and Health Psychology, Aarhus University Hospital & Aarhus University, Bartholins Allé 9, bygn. 1340, DK-8000 Aarhus C, Denmark.
  • Christensen S; Unit for Psychooncology and Health Psychology, Aarhus University Hospital & Aarhus University, Bartholins Allé 9, bygn. 1340, DK-8000 Aarhus C, Denmark.
  • Mehlsen M; Unit for Psychooncology and Health Psychology, Aarhus University Hospital & Aarhus University, Bartholins Allé 9, bygn. 1340, DK-8000 Aarhus C, Denmark.
  • Jensen AB; Department of Oncology, Aarhus University Hospital, Nørrebrogade 44, DK-8000 Aarhus C, Denmark.
  • Pedersen AD; Vejlefjord Rehabilitation, Sanatorievej 27b, DK-7140 Stouby, Denmark.
  • Zachariae R; Unit for Psychooncology and Health Psychology, Aarhus University Hospital & Aarhus University, Bartholins Allé 9, bygn. 1340, DK-8000 Aarhus C, Denmark.
Br J Cancer ; 113(5): 794-801, 2015 Sep 01.
Article en En | MEDLINE | ID: mdl-26171932
ABSTRACT

BACKGROUND:

There is growing concern among breast cancer (BC) patients and survivors about cognitive impairment following systemic treatments. The aim of the present study was to investigate the long-term effects of standard systemic adjuvant therapies on subjective cognitive impairment (SCI) in a large nationwide cohort of BC survivors 7-9 years after primary surgery.

METHODS:

Participants were recruited from the nationwide Psychosocial Factors and Breast Cancer inception cohort of Danish women treated for primary BC. SCI was assessed with the Cognitive Failures Questionnaire and women allocated to systemic treatment according to nationwide standard protocols were compared with women who had not received any systemic treatments.

RESULTS:

A total of 1889 recurrence-free survivors were eligible for analysis. No difference in SCI was found between survivors across standardized systemic treatment protocols when analyses were stratified by menopausal status and adjusted for possible sociodemographic and treatment-related confounders. The frequency of significant SCI in a subgroup of survivors in the age range 65-74 years was ∼7%.

CONCLUSIONS:

No differences in long-term SCI at 7-9 years post surgery were found between women who had received systemic therapies and those who had not. Furthermore, the observed proportion of survivors with significant SCI was comparable to normative data. These results are important to communicate to patients, survivors, and clinicians alike, especially in the light of increasing concern about cognitive impairment following systemic therapies.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Cognición Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Qualitative_research Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Br J Cancer Año: 2015 Tipo del documento: Article País de afiliación: Dinamarca

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Cognición Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Qualitative_research Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Br J Cancer Año: 2015 Tipo del documento: Article País de afiliación: Dinamarca